Literature DB >> 16697321

Effects of time, dose, and inversion time for acute myocardial infarct size measurements based on magnetic resonance imaging-delayed contrast enhancement.

Anja Wagner1, Heiko Mahrholdt, Louise Thomson, Stefan Hager, Gabriel Meinhardt, Wolfgang Rehwald, Michele Parker, Dipan Shah, Udo Sechtem, Raymond J Kim, Robert M Judd.   

Abstract

OBJECTIVES: This study sought to investigate the influence of time, dose, and inversion time (TI) and their interactions on myocardial infarct size measurements to establish the foundation for a standardized protocol for multicenter trials.
BACKGROUND: There is growing interest in using magnetic resonance imaging (MRI) infarct size measurements as an end point in clinical trials. However, no standardized protocol exists, and there are limited data concerning the effects of time, contrast agent dose, and TI.
METHODS: First, we determined the influence of postcontrast imaging time (5 to 40 min), contrast agent dose (0.1 vs. 0.2 mmol/kg), TI, and their interactions in an animal model (n = 14). Second, we tested whether the findings of the animal study apply to patients and are generalizable. Therefore, we retested the diagnostic window in a multicenter study. A total of 48 patients with first acute myocardial infarction (AMI) from three centers were imaged twice (5 and 30 min) after injection of 0.15 mmol/kg gadolinium diethylenetriamine-pentaacetate using an adjusted TI.
RESULTS: The animal study showed that the infarct size is independent of time and dose (p = 0.9 and p = 0.16, respectively) using an adjusted TI. Using a fixed TI, however, infarct size is a function of time and dose (p = 0.0001 and p = 0.01, respectively). The multicenter study showed that MRI 1 (16.9 +/- 12% of left ventricle) was not statistically different from MRI 2 (16.4 +/- 12% of left ventricle, p = NS) with no difference between sites (p = NS).
CONCLUSIONS: The AMI size can be measured with MRI using a contrast dose between 0.1 and 0.2 mmol/kg and a time window of 5 to 30 min after contrast administration, provided that the TI is adjusted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16697321     DOI: 10.1016/j.jacc.2006.01.059

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  38 in total

Review 1.  Identifying the etiology: a systematic approach using delayed-enhancement cardiovascular magnetic resonance.

Authors:  Annamalai Senthilkumar; Maulik D Majmudar; Chetan Shenoy; Han W Kim; Raymond J Kim
Journal:  Heart Fail Clin       Date:  2009-07       Impact factor: 3.179

2.  Quantitative inversion time prescription for myocardial late gadolinium enhancement using T1-mapping-based synthetic inversion recovery imaging: reducing subjectivity in the estimation of inversion time.

Authors:  Sebastian Gassenmaier; Rob J van der Geest; U Joseph Schoepf; Pal Suranyi; Wolfgang G Rehwald; Carlo N De Cecco; Domenico Mastrodicasa; Moritz H Albrecht; Domenico De Santis; Virginia W Lesslie; Balazs Ruzsics; Akos Varga-Szemes
Journal:  Int J Cardiovasc Imaging       Date:  2018-01-05       Impact factor: 2.357

Review 3.  Cardiac magnetic resonance imaging in heart failure: where the alphabet begins!

Authors:  Ahmed Aljizeeri; Abdulbaset Sulaiman; Naji Alhulaimi; Ahmed Alsaileek; Mouaz H Al-Mallah
Journal:  Heart Fail Rev       Date:  2017-07       Impact factor: 4.214

4.  Effect of inversion time on the precision of myocardial late gadolinium enhancement quantification evaluated with synthetic inversion recovery MR imaging.

Authors:  Akos Varga-Szemes; Rob J van der Geest; U Joseph Schoepf; Bruce S Spottiswoode; Carlo N De Cecco; Giuseppe Muscogiuri; Julian L Wichmann; Stefanie Mangold; Stephen R Fuller; Pal Maurovich-Horvat; Bela Merkely; Sheldon E Litwin; Rozemarijn Vliegenthart; Pal Suranyi
Journal:  Eur Radiol       Date:  2017-01-03       Impact factor: 5.315

Review 5.  Infarct characterization using CT.

Authors:  Ludovico La Grutta; Patrizia Toia; Erica Maffei; Filippo Cademartiri; Roberto Lagalla; Massimo Midiri
Journal:  Cardiovasc Diagn Ther       Date:  2017-04

6.  The role of cardiac magnetic resonance imaging following acute myocardial infarction.

Authors:  Dennis T L Wong; James D Richardson; Rishi Puri; Adam J Nelson; Angela G Bertaso; Karen S L Teo; Matthew I Worthley; Stephen G Worthley
Journal:  Eur Radiol       Date:  2012-03-25       Impact factor: 5.315

Review 7.  Cardiac MRI: a central prognostic tool in myocardial fibrosis.

Authors:  Bharath Ambale-Venkatesh; João A C Lima
Journal:  Nat Rev Cardiol       Date:  2014-10-28       Impact factor: 32.419

8.  T1 Mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy.

Authors:  Christopher T Sibley; Radwa A Noureldin; Neville Gai; Marcelo Souto Nacif; Songtao Liu; Evrim B Turkbey; James O Mudd; Rob J van der Geest; João A C Lima; Marc K Halushka; David A Bluemke
Journal:  Radiology       Date:  2012-10-22       Impact factor: 11.105

9.  Advanced methods for quantification of infarct size in mice using three-dimensional high-field late gadolinium enhancement MRI.

Authors:  Steffen Bohl; Craig A Lygate; Hannah Barnes; Debra Medway; Lee-Anne Stork; Jeanette Schulz-Menger; Stefan Neubauer; Jurgen E Schneider
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-02-13       Impact factor: 4.733

Review 10.  Cell therapy in myocardial infarction: emphasis on the role of MRI.

Authors:  Yuxiang Ye; Jan Bogaert
Journal:  Eur Radiol       Date:  2007-10-09       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.